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Abstract. ß-hydroxy-ß-methylbutyrate (HMB), a leucine
metabolite, improves muscle mass and function. This study
aimed at evaluating the effects of HMB administration in an
experimental in vivo model of cancer cachexia (CC). Wistar
rats were randomized to receive standard or 4% HMB-
enriched chow. Rats from both groups were randomized to
receive an i.p. inoculum of AH-130 cells (TB). All rats were
weighed and sacrificed at day 24. Liver, heart and muscles
were dissected and weighed. The protein levels of p-p70S6k,
p-eIf2·, p-mTOR and p-4-EB-P1 were evaluated by Western
blotting on gastrocnemius muscle (GSN). As expected, the
growth of the AH-130 ascites hepatoma induced significant
carcass weight and GSN muscle loss. HMB treatment signi-
ficantly increased GSN and heart weight in controls (p=0.002
and p<0.001, respectively). In HMB-treated TB, body weight
was not lost but significantly (p=0.003) increased, and GSN
loss was significantly (p=0.04) attenuated with respect to
TB. Phosphorylated eIF2· markedly decreased in TB-rats
vs. C. Feeding the HMB-enriched diet resulted in decreased
p-eIF2· levels in control animals, while no changes could be
observed in the TB group. Phosphorylated p70S6K and
phosphorylated mTOR were markedly increased by HMB
treatment in controls and further increased in TB. Phosphory-
lated 4-EB-P1 was markedly increased in TB but substantially
unaffected by HMB treatment. Administration of HMB
attenuates body weight and muscle loss in experimental CC.
Increased phosphorylation of key anabolic molecules suggests
that these actions are mediated by improved protein anabolism
in muscle.
Introduction
Cancer cachexia is a devastating syndrome characterized by
loss of body weight and muscle mass which affects patients'
morbidity, mortality and quality of life (1). Muscle loss has
serious clinical consequences such as decline in functional
status, increased disability risk and alteration of respiratory
muscle function (2).
In normal conditions, muscle mass is maintained by equal
rates of protein synthesis and degradation. In catabolic
conditions, this balance is shifted towards loss of muscle
tissue by increased muscle protein breakdown (3). The ATP-
ubiquitin-dependent system (4) plays a pivotal role in protein
degradation in wasting conditions, although the lysosomal
compartment (5), the Ca2-dependent proteolysis (6) and
caspases (7) may be involved as well.
Besides the degradative pathways, however, recent data
suggest that anabolic pathways might also be involved. In
particular, the potential role of insulin-like growth factor-1
(IGF-1) and myostatin in the pathogenesis of cancer cachexia
have gained particular attention during recent years (8,9).
Despite several lines of evidence showing that body
weight loss and muscle depletion are associated to a worse
outcome, no effective treatment for cancer cachexia is
available. Therefore, cancer cachexia remains a major plague
in clinical practice in need of effective preventative or thera-
peutic remedies.
One potential strategy could be to use targeted nutritional
supplementation aimed at stimulating the process of protein
synthesis and attenuating protein breakdown.
ß-hydroxy-ß-methylbutyrate (HMB) is a metabolite of the
branched-chain amino acid leucine (LEU), formed by trans-
amination to ·-ketoisocaproate in muscle followed by
oxidation of the ·-ketoisocaproate in the cytosol of the liver,
and possibly other tissues (10). Both LEU and ·-ketoiso-
caproate have been proposed to decrease nitrogen and protein
loss during periods of excessive catabolism (as severe stress
or trauma) (11) through the production of HMB, thought to
be responsible for the inhibitory effect on protein breakdown
(12).
HMB appears to exert its effect by attenuation of PIF-
induced increase of the ubiquitin proteasome pathway through
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the inhibition of PKC (protein kinase-C), with resultant stabi-
lization of the cytoplasmic IκB/NF-κB complex (13). HMB
is also thought to stimulate protein syntesis (14), possibly by
attenuating the inhibition of protein synthesis which occurs
during cancer growth (15,16). It is noteworthy that the ongoing
investigation on the possible molecular mechanisms through
which HMB may exert its action on muscle trophism, is
concomitantly providing new insights into the better under-
standing that protein degradation and synthesis are not
separate pathways. Indeed, cross-talk signalling between
protein degradative and synthetic pathways will either favour
muscle degeneration or regeneration.
Clinical studies have shown the ability of HMB to
increase lean body mass and muscle strength in humans
undergoing progressive resistance-exercise training (17) and
to attenuate signs and symptoms of exercise-induced muscle
damage in non-resistance trained healthy subjects (18). In
addition, the administration of a mixture containing HMB,
arginine and glutamine in advanced stage (IV) cancer
patients has shown efficacy in increasing both body mass and
fat-free mass with respect to controls (19), but these data
were not confirmed in a recent study in stage III-IV cancer
patients (20). Positive results were observed in AIDS (21,22),
but not in rheumatoid arthritis patients (23). Finally, HMB
alone was shown to improve nitrogen balance in trauma
patients (24), and to exert anti-inflammatory actions and to
improve respiratory function in critically ill COPD patients
(25). It should be noted, however, that not all clinical studies
support the efficacy of HMB supplementation. Possible
explanations for such conflicting results, are the variability
across human participants, the variability in human behaviour
(influenced by participant's social milieu, motivations, self-
confidence and current emotive status) and the inadequacy of
samples (number of patients studied and bias in sampling)
(26) as well as insufficient compliance and high drop-out rate
(20).
Finally, based on available evidence, HMB supplemen-
tation appears to be safe and not accompanied by undesired
side-effects either in animals (26) or humans (12) consuming
variable dosage. Gallagher et al have shown that an 8-week
HMB supplementation at different dosages have no adverse
effects on hepatic enzyme function, lipid profile, renal function
or on the immune system in untrained men undergoing
resistance training (27).
The aim of this study is to evaluate whether the early
administration of HMB alone may exert positive effects in an
experimental model of cancer cachexia (AH-130 Yoshida
ascites hepatoma) and to investigate if HMB interferes with
anabolic pathways within the muscle.
Materials and methods
The study was performed on male Wistar rats weighing ~150 g.
They were housed on a regular dark-light cycle (light from
8:00 am to 8:00 pm), with free access to food and water
throughout the experimental period, and cared for in comp-
liance with the Italian Ministry of Health Guidelines (no.
86609 EEC) and the NIH Guide for the care and use of
laboratory animals (NIH, 1996). After the acclimatation
period, rats were randomly divided into two groups to receive
standard (n=25) or an industrially-prepared 4% HMB-enriched
(n=31) pelleted chow (Mucedola, Settimo Milanese, Milan,
Italy). After 16 days, rats from both groups were randomized
to receive an i.p. inoculum of ~108 Yoshida AH-130 ascites
hepatoma cells (TB, n=12 and TB + HMB, n=15). Food and
water intake was measured daily by animal care personnel.
All rats were weighed, and sacrificed under light ether
anesthesia at day 24, eight days after tumor inoculum in the
TB groups. Immediately before death, blood was collected
from the abdominal aorta. The tumor was harvested from the
peritoneal cavity, and volume and cellularity were measured.
Liver, heart and muscles were rapidly excised, weighed,
frozen in liquid nitrogen, and stored at -80˚C until analysis.
Western blotting analysis. About 100 mg of gastrocnemius
muscle were homogenized in 80 mM Tris-HCl, pH 6.8
(containing 1 mM DTT, 70 mM SDS, and 1 mM glycerol),
kept on ice for 30 min, centrifuged at 15000 x g for 10 min at
4˚C, and the supernatant collected. Protein concentration was
assayed by the method of Lowry using BSA as working
standard. Equal amounts of protein (30 μg) were heat-
denaturated in sample-loading buffer (50 mM Tris-HCl, pH
6.8, 1 mM DTT, 2% SDS, 0.1% bromophenol blue, 10%
glycerol), resolved on an SDS-PAGE and transferred for 2 h
to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA).
Protein transfer was checked by Ponceau S staining. The
filters were then blocked with TBS containing 0.05% Tween
and 5% non-fat dry milk and incubated overnight with
primary antibodies specific for phosphorylated (p)-mTOR,
mTOR, p-eIF2·, eIF2·, p-4EBP, 4EBP, p-p70S6K, p70S6K
(Cell Signaling Technology, Danvers, MA, USA). All the
primary antibodies were diluted 1:1000 in TBS containing
0.05% Tween and 5% BSA. Goat anti-rabbit peroxidase-
conjugated IgG (Bio-Rad, Hercules, CA, USA) was used as
secondary antibodies. The filters were then stripped by
incubation in 62.5 mM Tris-HCl, pH 6.7, containing 100 mM
2-mercaptoethanol and 2% SDS for 30 min at 50˚C, and
reprobed with a mouse monoclonal antibody directed
against ·-tubulin (~50 kDa; Sigma, St. Louis, MO, USA) to
normalize sample loading. The membrane-bound immune
complexes were detected by an enhanced chemiluminescence
system (Santa Cruz Biotechnology, USA) on a photon-
sensitive film (Hyperfilm ECL; GE Healthcare, Milan, Italy).
Bands were then quantified by densitometry scanning of the
films and elaborated using a specific software (TotalLab,
NonLinear Dynamics, Newcastle upon Tyne, UK).
Data presentation. Results are expressed as means ± SD.
Significance of the differences has been evaluated using
Student's t-test for unpaired data. p<0.05 was considered
statistically significant.
Results
Effect of HMB administration on food intake. Cumulative
food intake was calculated for days 0-16 and 17-24 in all the
4 groups of rats (Table I). Rats treated with HMB showed a
reduction in cumulative food intake in period 0-16, which
was mainly accounted for by reduced food intake during the
first week (days 0-7).
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This was accompanied by a significant reduction in body
weight with respect to untreated animals at day 16. The growth
of the AH-130 ascites hepatoma (days 17-24, TB group) was
accompanied by a significant reduction in food intake, as it
was expected. However, HMB administration did not further
decrease food intake during tumor growth (day 17-24, TB +
HMB group).
When considering the whole study period (days 0-24),
HMB induced a significant reduction in food intake in both
controls and tumor bearing animals, with respect to untreated
rats (Table I). Total food intake (days 0-24) was similar in
TB rats and HMB-treated controls.
Effect of HMB administration on body, carcass and organ
weight. As expected, the growth of the AH-130 ascites hepa-
toma induced a significant carcass weight and muscle loss
(Table II). Treatment with HMB significantly prevented carcass
weight loss in tumor-bearing rats, as indicated by the weight
difference between day 16 (body weight) and day 24 (carcass
weight, not including ascites) (p=0.003 vs TB, Table II),
despite the reduction in total (days 0-24) food intake. Control
rats treated with HMB showed a slight but significant reduction
of body weight.
Loss of GSN muscle was also significantly attenuated by
HMB in TB rats (Table II). Interestingly, in normal rats HMB
induced a significant increase in GSN muscle and heart weight
with respect to untreated controls. No differences were noted
in the weight of soleus muscle, liver and spleen in both
treated and untreated rats (Table II). 
Effect of HMB administration on tumor growth. A slight, but
statistically significant reduction in tumor growth was observed
in HMB-treated tumor-bearing rats (data not shown). 
Effect of HMB administration on intramuscular molecular
pathways. Phosphorylated (p) eIF2· markedly decreased in
TB-rats vs. controls (Fig. 1). Although considerable, however,
this difference did not reach statistical significance, likely
due to variability among animals in the control group. Feeding
the HMB-enriched diet tended to decrease p-eIF2· levels in
control animals, while no changes could be observed in the
TB group (Fig. 1). Among the other kinases analysed in the
present study, mTOR and p70S6K showed a parallel trend,
since they both tended to be hyperphosphorylated in TB-rats
even if the trend did not reach or was at the limit of statistical
significance (Figs. 2 and 3). HMB administration to normal
rats proved effective in enhancing mTOR and p70S6K phos-
phorylation above control levels. Similarly, p-mTOR and p-
p70S6K were further increased, although not significantly in
HMB-treated TB in comparison with untreated TB (Figs. 2
and 3). Finally, TB-rats tended to have higher levels of p-4E-
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Table I. Food intake in control and tumor-bearing rats.
–––––––––––––––––––––––––––––––––––––––––––––––––
Food intake Total food intake








TB + HMB 122±18a 381±39c
(n=15)
–––––––––––––––––––––––––––––––––––––––––––––––––
ap<0.001 vs C; bp=0.046 vs C; cp=0.013 vs TB.
–––––––––––––––––––––––––––––––––––––––––––––––––
Table II. Body and tissue weight in treated and untreated rats.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Body weight Carcass weight ΔWTi GSN Soleus Heart Spleen Liver
day 16 (g) day 24 (g) (%IBW) (%IBW) (%IBW) (%IBW) (%IBW)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
C 205±15 252±18 49±5 0.63±0.05 0.04±0.01 0.32±0.03 0.32±0.04 5.8±0.5
(n=13)
C + HMB 186±16a 237±16c 51±5 0.68±0.03f 0.04±0.01 0.36±0.03d 0.32±0.04 5.8±0.5
(n=16)
TB 207±10 205±12d -3±7d 0.54±0.03d 0.04±0.01 0.30±0.02 0.32±0.03 5.4±0.3
(n=12)
TB + HMB 193±22b 207±24 14±16e 0.57±0.04f,g,h 0.04±0.01 0.31±0.04 0.33±0.05 5.2±0.6
(n=15)
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
For TB and TB + HMB rats, weight at day 24 is carcass weight (not including ascites). IBW%: percentage of initial body weight. ap=0.005
vs C; bp=0.045 vs TB; cp=0.021 vs C; dp<0.001 vs C; ep=0.003 vs TB; fp=0.002 vs C; gp=0.04 vs TB; hp<0.001 vs C + HMB. iΔWT: Body
weight difference between day 16 (tumour inoculum) and day 24 (sacrifice).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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BP1 (Fig. 4) with respect to control values, that were not
further modified by HMB administration. Similarly, HMB
did not exert any effect on p-4E-BP1 levels in the controls
(Fig. 4).
Discussion
ß-hydroxy-ß-methylbutyrate has been long proposed as an
anabolic agent and has been widely employed in sports
medicine to improve lean body mass and muscle strength in
subjects undergoing resistance training exercise (12,26) and
in the elderly (28). Two main mechanisms have been proposed
to explain the positive effects exerted by HMB, namely a
down-regulation of muscle protein degradation and the
attenuation of muscle damage likely achieved by stabilization
of the sarcolemma (12,13). The latter has been defined as the
cholesterol synthesis hypothesis. Most of the intracellular
HMB is converted into hydroxy-methyl-glutaryl-coenzyme-A
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Figure 1. (A) Densitometric analysis of Western blots for phosphorylated eIF2· in gastrocnemius muscle in C (n=13), HMB (n=16), TB (n=12) and TB + HMB
(n=15) animals. Data (means ± SD) represent the ratio between total and phosphorylated eIF2·; (B) Representative Western blot pattern of phosphorylated
and total eIF2·.
Figure 2. (A) Densitometric analysis of Western blot for phosphorylated mTOR in gastrocnemius muscle (ap=0.0029 vs C; bp=0.0216 vs HMB; cp=0.0415 vs
C) in C (n=13), HMB (n=16), TB (n=12) and TB + HMB (n=15) animals. Data (means ± SD) represent the ratio between total and phosphorylated mTOR;
(B) Representative Western blot pattern of phosphorylated and total mTOR.
713-720.qxd  26/1/2011  09:19 Ì  ™ÂÏ›‰·716
(HMG-CoA), one of the substrates in cholesterol biosyn-
thesis. In this regard, increased HMB availability within the
muscle would enhance cholesterol production, allowing
sarcolemma repair and stabilization (12,29,30). Not only, the
increased synthesis of mevalonic acid, the cholesterol
precursor deriving from HMG-CoA reductase activity, may
result in enhanced levels of coenzyme Q10 (31), the lack of
which has been proposed to play a role in the pathogenesis
of muscle atrophy (32,33). On the contrary, a single report
suggests that HMB might prevent muscle wasting by
decreasing the rates of protein catabolism through down-
regulation of the ATP-dependent ubiquitin-proteasome
pathway (15).
More recently, however, the hypothesis that HMB might
directly stimulate muscle protein anabolism has been propo-
sed. In this respect, a crucial step in the anabolic response is
phosphorylation and activation of the kinase mammalian
target of rapamycin (mTOR) (34) (Fig. 5), which in turn
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Figure 3. (A) Densitometric analysis of Western blot for phosphorylated p70S6K in gastrocnemius muscle (ap=0.05 vs C; bp=0.06 vs HMB) in C (n=13),
HMB (n=16), TB (n=12) and TB + HMB (n=15) animals. Data (means ± SD) represent the ratio between total and phosphorylated P70S6K; (B)
Representative Western blot pattern of phosphorylated and total P70S6K.
Figure 4. (A) Densitometric analysis of Western blot for phosphorylated 4-EB-P1 in gastrocnemius muscle (ap=0.02 vs C; bp=0.008 vs HMB) in C (n=13),
HMB (n=16), TB (n=12) and TB + HMB (n=15) animals. Data (means ± SD) represent the ratio between total and phosphorylated 4-EB-P1; (B)
Representative Western blot pattern of phosphorylated and total 4-EB-P1.
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activates p70S6 kinase (p70S6K) and inhibits 4E-BP1 (also
known as PHAS-1), positive and negative regulators of
translation initiation, respectively. The latter competes with
eIF4G for binding to eIF4E: when 4E-BP1 is hypophospho-
rylated, it tightly binds eIF4E to form the translationally
inactive eIF4E/4E-BP1 complex. By contrast, when 4E-BP1
is phosphorylated, eIF4E is released and presumably available
for binding to eIF4G (35). eIF4E, together with eIF4G and
EIF4A, forms the eIF4F complex, that is crucially involved
in mRNA translation (34). Phosphorylation of 4E-BP1 induced
by growth factors such as insulin and IGF-I has been shown
to depend on the Akt/PI3K/mTOR pathway (35), whereas
an Akt-unrelated, mTOR-dependent activation has been
proposed to results from increased intracellular amino acid
availability (35). In a parallel pathway, the eIF2 complex
formed by eIF2·, ß and Á, binds the Met-tRNA to the 40S
ribosomal subunit to form the 43S initiation complex. During
this process the eIF2-associated GTP is hydrolysed to GDP.
Recycling of eIF2-GDP to eIF2-GTP requires the guanine
nucleotide exchange factor eIF2B (36), whose activity is
induced via phosphorylation by the glycogen-synthase kinase
(GSK)-3ß (37). Several kinases can phosphorylate eIF2·,
leading to inhibition of eIF2B, and to consequent reduction
of eIF2-GTP levels, resulting in decreased translation (38).
In the present study the growth of the AH-130 ascites
hepatoma induced significant loss of carcass weight and
GSN muscle mass, which was comparable with our previous
observations in the same model (6,9). The data obtained
show that early HMB administration may attenuate loss of
muscle and body weight characteristic of cancer cachexia.
Indeed, in the AH-130 tumor-bearing rats, HMB treatment
not only prevented the anticipated body weight loss (39), but
was capable of inducing an increment in body weight following
tumor inoculum. Moreover, the loss of GSN muscle was
attenuated by HMB with respect to untreated tumor-bearing
rats. Attenuation of body weight and muscle loss occurred
despite reduction in total food intake, suggesting that the
anabolic effect of HMB may overcome the possible effects of
reduced nutrient availability. Conversely, in control rats,
although HMB treatment induced a reduction in food intake
associated with a reduction in body weight, a significant
increase in GSN muscle mass was observed. Despite total
(days 0-24) food intake was similar in C + HMB and TB rats,
carcass weight at day 24 was markedly and significantly
different between these groups (237±16.48 vs 204.58±11.94 g,
in TB and C + HMB, respectively, p<0.001), confirming that
the presence of the tumor per se, rather than reduced food
intake, has a major role in the pathogenesis of weight loss in
cancer cachexia.
Our results are in agreement with previous clinical and
experimental data suggesting that HMB may exert a positive
role in counteracting cancer-related wasting. May et al (19)
showed that the daily administration of 3 g HMB, in combi-
nation with arginine and glutamine, increases body weight
and lean body mass in advanced, cachectic cancer patients.
Smith and co-workers found that, in mice bearing the MAC-16
tumor, doses of HMB >0.125 g/kg significantly attenuate
weight loss and increase soleus muscle mass. These findings
were accompanied by reduced expression of proteasome
subunits, decreased proteasome chymotrypsin-like activity,
attenuated protein degradation and increased protein synthesis
rates within muscle tissue (15). Although we did not measure
protein synthesis, the present study suggests that, at least in
the AH-130 model of cancer cachexia, HMB administration
may prevent muscle wasting by modulating the activity of
molecules crucially involved in the anabolic response. Indeed,
the levels of phosphorylated mTOR and p70S6K, already
enhanced in the AH-130 hosts, further increased after HMB
treatment in both controls and tumor bearers, while those of
p-eIF2· further decreased in the latter. Similar effects of
HMB administration were observed by Eley and colleagues
in mice bearing the MAC-16 tumor, although, differently
from the AH-130 bearers, the state of activation of both
mTOR and p70S6K was reduced in the untreated MAC-16
hosts (16). The authors showed that 0.25 g/kg HMB may
reduce the level of phosphorylation of downstream molecules
involved in anabolic signaling, namely PKR and eIF2·. In
the same study, addition of HMB to C2C12 myotube cultures
was shown to increase the basal phosphorylation levels of
mTOR, p70S6K and 4E-BP1. Moreover, HMB was also able
AVERSA et al:  HMB IN CANCER CACHEXIA718
Figure 5. Schematic representation of mTOR signaling.
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to counteract the reduction of p-mTOR and p-p70S6K and to
increase the phosphorylation of 4E-BP1 in PIF-treated C2C12
cultures.
Unlike in this in vitro observation, in the present investi-
gation the phosphorylation of 4E-BP1 not only was greater in
tumor-bearing than in control rats, but it was also unaffected
by HMB in both control and tumor-bearing rats. These
differences, however, may well be due to the different
(in vitro vs in vivo) experimental settings. In our study, HMB
administration in controls rats did not influence 4E-BP1
phosphorylation in spite of the elevated level of p-mTOR:
possible explanations for this finding might be that phos-
phorylation of 4-EB-P1 is not solely dependent of mTOR
phosphorylation and/or it might be also influenced by a
specific phosphatase activity.
The results of the present study demonstrate that admi-
nistration of HMB improves cancer-related muscle wasting
and body weight loss. It is known that the AH-130 tumor
causes muscle atrophy mainly by enhancing muscle protein
catabolism, while the rates of synthesis remain comparable to
controls (40). Despite this, as shown in the present study the
skeletal muscle of the AH-130 hosts shows a pro-synthetic
molecular pattern, since the levels of p-mTOR, p-p70S6K
and p-4E-BP1 tend to be higher than in controls, while those
of p-eIF2· tend to be lower. These observations suggest that
in the AH-130-bearing rats the skeletal muscle, although
atrophying, retains the ability to activate a compensatory
anabolic response, that however does not result in synthesis
rates above those of controls. HMB administration, while
ineffective in modifying the levels of both p-eIF2· and p-4E-
BP1, further increases mTOR and p70S6K phosphorylation.
HMB could therefore boost protein synthesis by increasing
the phosphorylation of the ribosomal protein S6, that works
as an adaptor between the 40S and 60S ribosomal subunits
(41). Future studies will be aimed at verifying this point, by
concomitantly measuring protein synthetic rate in muscle.
A major concern in nutritional supplementation in cancer
is the theoretical risk of feeding the tumor, particularly when
molecules with claimed anabolic actions are used. However,
the data obtained in the present investigation, in agreement
with what previously shown by others (15) would suggest
that HMB reduces tumor growth. The mechanisms under-
lying this positive effect are unclear, and deserve further
investigation. It could be argued that the protective effects
exerted on muscle and body weight by HMB supplementation
in tumor-bearing rats might be indeed secondary to decreased
tumor growth. However, this concern is weakened by the
clearcut effects of HMB on muscle weight and signaling
molecules achieved in controls, which strengthens the view
that the anti-cachectic effects are mainly mediated by a direct
HMB effect on muscle metabolism.
In conclusion, the results obtained in the present study
suggest that HMB is associated with attenuation of muscle
loss in an experimental model of cancer cachexia. Preservation
of muscle mass is associated to increased phosphorylation of
key anabolic molecules, suggesting that HMB action is
mediated by improved protein anabolism in muscle. No such
similar concomitant phenotypical benefits and molecular
changes were observed in intervention studies in this model.
The administration of HMB alone or in combination with
other drugs and/or nutrients might represent a safe and
effective way to prevent (42,43) the loss of lean body mass in
cancer cachexia. Finally, the hypothesis that HMB administra-
tion may attenuate muscle mass and body weight loss through
a reduction of tumor growth deserves further investigation.
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